The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | IO-local therapy combinations in NSCLC: defining resectability limits
Yannis Perentes, MD, PhD, University of Lausanne, Lausanne, Switzerland,
discusses the current evidence indicating immunotherapy (IO)-local therapy
combinations for non-small cell lung cancer (NSCLC). Ongoing discussions
defining cancer resectability and non-resectability attempt to create common
language across specialties to determine the limits of this approach. This
interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are
protected by copyright laws and treaties around the world. All rights are
reserved.
